Summary by Futu AI
On June 20, 2024, SenesTech, Inc., a biotechnology company based in Phoenix, Arizona, announced the entry into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. Under this agreement, SenesTech may offer and sell shares of its common stock at its discretion in 'at the market' offerings, potentially raising aggregate gross proceeds of up to $1,575,944. The sales will be conducted pursuant to a shelf registration statement and related prospectus supplement filed with the SEC. The agreement allows Wainwright to sell shares through various methods, including directly on the Nasdaq, where SenesTech's common stock is listed under the symbol SNES. SenesTech is not obligated to sell any specific number of shares, and Wainwright will act based on SenesTech's instructions, subject to a 3.0% placement fee on the gross sales price. The offering will terminate upon reaching the maximum sales amount or by mutual termination of the agreement. The company has also provided customary indemnification rights to Wainwright and will reimburse certain expenses related to the agreement.